Project Grant K99DA058761
- This project grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports fundamental neuroscience research investigating the neural mechanisms linking stress exposure to opioid use disorder initiation. The University of South Carolina received $192,149 to conduct a two-year research project (February 1, 2026 through January 31, 2028) examining noradrenergic circuit mechanisms in stress-induced opioid-seeking behavior....
- This $109,076 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research examining the relationship between ovarian steroid hormones and cannabis use patterns in reproductive-aged females. The project, awarded to the University of Illinois on January 25, 2026, with completion anticipated by January 24, 2030, addresses a critical gap in understanding why females exhibit faster progression to Cannabis...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Columbia University's Health Sciences Division a $1.49M Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining the impact of cannabis use disorder (CUD) and its treatment on opioid-related health consequences among Veterans Health Administration (VHA) patients. The research addresses a critical gap in the literature by investigating associations...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Icahn School of Medicine at Mount Sinai a $507,000 Project Grant, effective September 1, 2025 through May 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award supports research investigating the epigenetic basis of tetrahydrocannabinol (THC) consumption and cannabis use disorder (CUD). The project utilizes a translational preclinical model of volitional THC consumption in animal...
- The Medical University of South Carolina received a $675,129 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective April 1, 2026, through January 31, 2031. The grant supports the development and evaluation of COPE-A (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure, adapted for Adolescents), an integrated, trauma-focused intervention designed to address the critical gap in...
- Federal Grant Award Summary The University of California, San Diego received a $158,246 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period July 1, 2025 through June 30, 2027. This award supports research investigating the co-occurrence of posttraumatic stress disorder (PTSD) and substance use disorder (SUD) across developmental stages from childhood through adulthood. The project adopts a developmental...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and evaluate an adapted version of Written Exposure Therapy (WET) for treating posttraumatic stress disorder (PTSD) among individuals with opioid use disorder (OUD) in residential substance use disorder (SUD) treatment settings. The $798,605 award will fund a multi-site study to create and test the adapted "Written Exposure in...
- Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded a $1.37 million Cooperative Agreement to New York University School of Medicine, effective July 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test a telehealth-delivered transcranial direct current stimulation (tDCS) intervention for cannabis use disorder (CUD). The C.A.R.E.S. (Cannabis Addiction Recovery Enhancement Stimulation) Initiative combines home-based...
- Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $385,638 to The Regents of the University of Colorado (University of Colorado-Denver) under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2025, with a completion date of August 31, 2028. This research award funds a three-year neurobehavioral investigation titled "Cannabinoid Tolerance Across Neurodevelopment: Disruption of Value-Driven Behavior and Prevention Through...
- Federal Grant Award Summary Oregon Health & Science University received a $791,990 Project Grant award effective June 15, 2025, from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal mechanistic study examining reciprocal relationships between cannabis use, sleep, and hypothalamic-pituitary-adrenal (HPA) axis functioning. The three-year research initiative (completion date April 30, 2030) will enroll 60...
NEUROBIOLOGICAL MECHANISMS UNDERLYING CHANGES IN PTSD-LIKE SYMPTOMS AFTER CANNABIS USE - PROJECT SUMMARY/ABSTRACT: POST-TRAUMATIC STRESS DISORDER (PTSD) HAS A HIGH RATE OF COMORBIDITY WITH CANNABIS USE DISORDER (CUD). INDEED, IN VETERANS DIAGNOSED WITH CUD, PTSD IS THE MOST HIGHLY CO-OCCURRING DISEASE. MOREOVER, PATIENTS WITH COMORBID PTSD AND CUD HAVE GREATER DRUG USE SEVERITY AND SHOW POORER TREATMENT OUTCOMES THAN PATIENTS DIAGNOSED WITH EITHER PTSD OR CUD ALONE. CONVERSELY, PTSD IS OFTEN LISTED AS A MEDICAL CONDITION POTENTIALLY AMELIORATED BY CANNABIS USE. HOWEVER, THE CLINICAL LITERATURE IS MIXED REGARDING THE EFFECT OF CANNABIS USE ON PTSD SYMPTOMS, WITH SOME EARLIER STUDIES INDICATING CANNABIS USE MAY SELF- MEDICATE PTSD AND NEWER LITERATURE ARGUING THAT IT EXACERBATES PTSD SYMPTOMS AND REDUCES TREATMENT EFFICACY. THUS, THE PREVALENCE OF PTSD/CUD COMORBIDITY AND THE INCREASING LEGAL STATUS OF CANNABIS IN UNITED STATES MAKE IT IMPERATIVE TO UNDERSTAND THE MECHANISMS WHEREBY CANNABIS USE IS POTENTIALLY PROMOTING OR AMELIORATING PTSD SYMPTOMS. USING ACUTE RESTRAINT STRESS COMBINED WITH A RAT CANNABIS SELF-ADMINISTRATION PARADIGM, I RECENTLY FOUND THAT CANNABIS USE PROMOTES TWO PRIMARY PTSD-LIKE SYMPTOMS, AVOIDANCE COPING BEHAVIORS (IMMOBILITY IN THE DEFENSIVE BURYING TASK) AND THE GENERALIZATION OF STRESS COPING RESPONSES TO A NEUTRAL STIMULUS NOT PREVIOUSLY ASSOCIATED WITH STRESS EXPOSURE. THESE CLINICALLY RELEVANT DISCOVERIES ARE THE FOUNDATION FOR MY K99/R00 PATHWAY TO INDEPENDENCE PROPOSAL. THIS PROPOSAL AIMS TO IDENTIFY NEUROBIOLOGICAL MECHANISMS UNDERPINNING HOW CANNABIS USE CHANGES AND POTENTIALLY EXACERBATES PTSD-LIKE SYMPTOMS. DURING THE K99 PORTION, I WILL CHARACTERIZE, IN A CELL-SPECIFIC MANNER, THE NEUROADAPTATIONS INDUCED BY THE INTERACTION BETWEEN STRESS AND CANNABIS USE IN THE NUCLEUS ACCUMBENS CORE (NACORE). TO THIS END, I WILL COMBINE IN VIVO ZYMOGRAPHY WITH CONFOCAL MICROSCOPY AND DIGITAL RENDERING APPROACHES TO QUANTIFY CHANGES IN THE TETRAPARTITE SYNAPTIC PLASTICITY, WHICH INCLUDES CHANGES IN: MORPHOLOGY OF D1- AND D2-MEDIUM SPINY NEURONS (MSNS), ASTROGLIA, AND THE EXTRACELLULAR MATRIX (ECM) (AIM 1). I WILL THEN USE THE IN VIVO SINGLE-CELL CA2+ RECORDING FROM D1- AND D2-MSNS IN NACORE, TO DETERMINE WHICH CELL TYPE AND WHAT PATTERNS OF ACTIVITY ARE ASSOCIATED WITH THE EXACERBATING EFFECTS OF CANNABIS USE ON STRESS RESPONSES (AIM 2). IN THE R00 PORTION, I WILL APPLY MY K99 TRAINING TO STUDY HOW STRESS AND CANNABIS AFFECT THE TETRAPARTITE SYNAPTIC PLASTICITY IN VENTRAL PALLIDUM (VP), A PRIMARY ACCUMBENS OUTPUT NUCLEUS THAT TRANSLATES REWARDING AND AVERSIVE STIMULI INTO BEHAVIORAL RESPONSES. I WILL ASSESS THE SIGNALING BETWEEN ECM, ASTROCYTE AND GABAERGIC NEURONS (VPGABA), AS WELL AS THE EXPRESSION OF PERINEURONAL NETS (PNNS) FOLLOWING ACUTE STRESS AND CANNABIS USE (AIM 3A). I WILL THEN EVALUATE THE SPECIFIC ROLE OF PNNS IN THE ALTERING EFFECTS OF CANNABIS USE ON STRESS RESPONSES (AIM 3B). FINALLY, I WILL USE CHANGES IN INTRACELLULAR CA2+ TO DETERMINE IF EXPOSURE TO STRESS-CONDITIONED STIMULI OR NEUTRAL STIMULI CHANGES THE ACTIVITY OF VPGABA AFTER CANNABIS USE (AIM 4). BY EXAMINING TETRAPARTITE PLASTICITY IN A BRAIN CIRCUIT KNOWN TO STRONGLY REGULATE BOTH REWARD AND AVOIDANCE BEHAVIORS, I EXPECT TO IDENTIFY NEW TARGETS FOR REGULATING PTSD AND CUD COMORBIDITY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 3/12/26 | ||
| Not listed | $194.6k | 3/24/25 | ||
| Not listed | $187.2k | 4/26/24 | ||
| Not listed | $187.2k | 4/26/24 |